Migraine Physical Function Impact Diary (MPFID)
Understand the multifaceted impact migraine has on patients
Migraines are more than headaches; they can cause debilitating pain, limiting physical functioning. The Migraine Physical Function Impact Diary (MPFID) is a 13-item self-report questionnaire developed to measure the subjective impact of migraine on physical functioning (everyday activities and physical impairment) in the past 24 hours. It is intended for use in adults (age 18 or older) with episodic migraine (EM) or chronic migraine (CM), with or without aura.
This measure was developed using methods consistent with the regulatory guidance on patient-reported outcome (PRO) measures to support label claims about the benefit of treatments (FDA Guidance, 2009).
The MPFID was designed to be completed daily to capture the day-to-day variability of the impact of migraine on migraine and non-migraine days. It was conceptually designed to capture both ”acts” and ”tasks” associated with the impact of migraine on functioning. The MPFID includes multiple domains to assess the impact of migraine on physical functioning:
Impact on everyday activities
The Impact Everyday Activities (EA) domain includes seven items and generates a domain score addressing impacts on everyday activities, such as household chores, activities outside the home and activities requiring concentration.
Physical impairment
The Physical Impairment (PI) domain includes five items and generates a domain score addressing the impact on physical function, such as moving the head or body and getting out of bed.
Overall impact on everyday activities
The Overall Impact on Everyday Activities is a standalone question assessing the global impact of migraine on doing usual activities.
Licensing information
As the contracted agency approved by the MPFID copyright holder (Amgen Inc.) to license and distribute the MPFID, we uphold our responsibility to protect the integrity of the MPFID as it is distributed for use, including developing translations and adaptations.
A user agreement is required for all requests to use the MPFID in research and use is granted for a single study only. Fees for licensure vary depending on the type of user making the request and nature of the research. To inquire about terms and fees for licensure to use the MPFIQ, please choose the appropriate affiliation below to submit your interest, and you will be contacted by a clinical outcome assessment (COA) expert with information relevant to your needs.
Translations available
The MPFID is available in paper-pencil format and ePRO format in multiple languages. The following language versions are available:
Scroll the table to view available translations.
| Language | Country |
|---|---|
| Bulgarian | Bulgaria |
| Czech | Czech Republic |
| Danish | Denmark |
| Dutch Universal | Belgium/Netherlands |
| English Universal | Australia/Canada/United Kingdom/United States |
| Finnish | Finland |
| French Universal | Belgium/Canada/France/Switzerland |
| German Universal | Austria/Germany/Switzerland |
| Greek | Greece |
| Hungarian | Hungary |
| Italian Universal | Switzerland |
| Norwegian | Norway |
| Polish | Poland |
| Portuguese Universal | Portugal |
| Romanian | Romania |
| Russian Universal | Russia |
| Slovak | Slovakia |
| Spanish Universal | Mexico/Spain/United States |
| Swedish | Sweden |
| Turkish | Turkey |
While the list of available translations is extensive, the process for any additional translations needed is outlined below:
- We must conduct all translation work using our preferred vendors who have a history with this COA
- Standardized methods for COA translation are followed and certification letters are provided
- Please provide your language needs on your submission form, and you will be provided with a cost estimate and timeline with our reply to the details of your project
Explore the MPFID resources
The MPFID is supported by professional publications and scientific presentations.